Solanezumab

Lilly targets tau in Alzheimer's effort

By

Lilly is upping its bet on Alzheimer's. The Indianapolis-based drug maker announced it has licensed experimental tracers that can hone in on and mark tau tangles that are believed to be a cause of the brain-degenerating disease.